First AD

Second AD

Stephen Liu, MD, is an associate professor of medicine at Georgetown University, as well as the director of Thoracic Oncology and head of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center in Washington, DC.

Patient Profile and Treatment Selection in ALK+ NSCLC

Panelists explain that therapy decisions should consider patient characteristics such as performance status, comorbidities, and tolerance to potential side effects. Older adults and those with cardiac or metabolic risk factors may require dose adjustments or alternative regimens.

Shared decision-making is highlighted as an essential part of treatment planning. Discussing potential side effects and lifestyle implications helps patients engage actively in their care, improving adherence and satisfaction.

The segment concludes that tailoring treatment intensity and monitoring plans to each patient’s clinical profile ensures safer, more effective long-term management of ALK-positive disease.

Clinical

® Clinical Focus page includes a listing of all specialities covered across  OncLive.com, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, hematologic malignancies, and gynecologic cancers. Each individual specialty page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research.


Video Series

Oncodrivers in Advanced or Metastatic NSCLC: Current and Future Standards of Care

Peer Exchange

Panelists discuss individualized treatment selection based on age, comorbidities, and patient preferences in ALK-positive lung cancer.